ACR
ACRUX LIMITED
$0.0110
▼ -15.38%
Market cap
$7M
Turnover
$47,288
Last price
$0.0110
Day change
-15.38%
Announcements
15
Range, past year
Open 0.015 · Low 0.009 · Now 0.011 · High 0.027
Open ACR in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
ACR momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-10-13.
Momentum quality
20/100
Wyckoff phase
Accumulation8d
Trend stage
Emerging
1 Day
-15.4%
1 Week
+10.0%
1 Month
+10.0%
1 Year
-21.4%
RSI
55
Avg daily range
8.2%
ACRUX LIMITED scores 20 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Emerging.
On the Wyckoff cycle it sits in Accumulation, where it has been for 8 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.
Against the wider market it is currently outperforming and the institutional accumulation signal reads low.
Points to watch
- 60d drawdown -25.0%
- High volatility (ATR 8.2%)
- Thin liquidity
- Risk rating: Very High
- Composite downside risk elevated
ACR announcements
Recent price-sensitive releases.
- 2026-10-12 FDA clears regulatory pathway for Female Testosterone MDTS Web Cast | Progress Report
- 2026-10-02 Acrux has received $1.977m RDTI rebate for FY26 Periodic Reports - Other
- 2026-08-26 FY26 Annual Report and Appendix 4E Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-08-06 Investor Presentation - Female Testosterone for HSDD Company Presentation
- 2026-07-31 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-05-29 Update - Licensing Lenzetto for Australia for AUD5.4m
- 2026-05-28 Acrux licenses Lenzetto for Australian market for AUD5.4m
More Health Care stocks
Most traded in the same sector.